Search alternatives:
nm decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
w decrease » we decrease (Expand Search), _ decrease (Expand Search), _ decreased (Expand Search)
5 w » 5 wt (Expand Search)
Showing 141 - 160 results of 100,594 for search '(( 5 ((((nm decrease) OR (a decrease))) OR (mean decrease)) ) OR ( 5 w decrease ))', query time: 1.60s Refine Results
  1. 141
    Mutation of Ser-473 in GC-A to alanine but not glutamate decreases ANP-stimulated guanylyl cyclase activity.

    Mutation of Ser-473 in GC-A to alanine but not glutamate decreases ANP-stimulated guanylyl cyclase activity. by Andrea R. Yoder (165684)

    Published 2012
    Save to List
    Saved in:
  2. 142
    Fluorescence intensity curves of <i>M</i>. <i>aeruginosa</i> after H<sub>2</sub>O<sub>2</sub> and light treatments from UV, violet, blue, yellow-green, red laser excitation.

    Fluorescence intensity curves of <i>M</i>. <i>aeruginosa</i> after H<sub>2</sub>O<sub>2</sub> and light treatments from UV, violet, blue, yellow-green, red laser excitation. by Emma T. Brentjens (17295999)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  3. 143
    Time-resolved EELS spectra, as a function of decreasing water vapor pressure.

    Time-resolved EELS spectra, as a function of decreasing water vapor pressure. by Cathal Cassidy (1758703)

    Published 2017
    Save to List
    Saved in:
  4. 144
    Acetylcholine-induced NO- and EDHF-mediated relaxations decrease with increasing age.

    Acetylcholine-induced NO- and EDHF-mediated relaxations decrease with increasing age. by Noureddine Idris Khodja (331400)

    Published 2013
    Save to List
    Saved in:
  5. 145
    Decrease of actin velocity when passing confined TCR clusters.

    Decrease of actin velocity when passing confined TCR clusters. by Cheng-han Yu (244912)

    Published 2010
    Save to List
    Saved in:
  6. 146
    Early increase and later decrease in GSK-3β activity.

    Early increase and later decrease in GSK-3β activity. by Arie J. Hoogendijk (353624)

    Published 2013
    Save to List
    Saved in:
  7. 147
    Conventional dynamic latch comparator [13], [14].

    Conventional dynamic latch comparator [13], [14]. by Labonnah Farzana Rahman (641767)

    Published 2014
    Subjects:
    Save to List
    Saved in:
  8. 148
    Chronic, sublethal neonicotinoid exposure decreases cumulative weight gain and cluster size of honey bee colonies.

    Chronic, sublethal neonicotinoid exposure decreases cumulative weight gain and cluster size of honey bee colonies. by Sarah C. Wood (4730634)

    Published 2018
    Save to List
    Saved in:
  9. 149
    Performance comparison of the proposed dynamic latch comparator.

    Performance comparison of the proposed dynamic latch comparator. by Labonnah Farzana Rahman (641767)

    Published 2014
    Subjects:
    Save to List
    Saved in:
  10. 150
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 151
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 152
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 153
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 154
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 155
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 156
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 157
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 158
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 159
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 160
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: